Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134459 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Bifeprunox in Bipolar Depression
A Phase 3 study of Bipolar Disorder, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 434
- Enrollment target
- 20
- Study locations
NCT00134459: Completed Phase 3 study of Bipolar Disorder, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00134459 is a Phase 3 study of Bipolar Disorder that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 434 participants, above the 330-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134459, a Phase 3 study of Bipolar Disorder, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 434 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bifeprunox
Study Locations (20)
Florida
- - Bradenton
- - Jacksonville
- - Orlando
- - West Palm Beach
California
- - Beverly Hills
- - National City
- - Stanford
New Jersey
- - Clementon
- - Moorestown
Alabama
- - Birmingham
Connecticut
- - Farmington Hills
Georgia
- - Smyrna
Hawaii
- - Honolulu
Indiana
- - Terre Haute
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
What the finished NCT00134459 record still lists
NCT00134459 is an interventional study that assigns participants to a tested intervention. The registered 434 participants enrollment target is mid-sized for trials with a published cap, above the 330-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (32% higher).
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00134459 names 20 study sites across 14 states, led by Florida, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00134459 about?
NCT00134459 is a clinical study titled "Study Evaluating Bifeprunox in Bipolar Depression". The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
What is the current status of trial NCT00134459?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 434 participants. The study started on 2005-06. Estimated completion is 2006-05.
What conditions does trial NCT00134459 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT00134459?
The interventions under investigation include: Placebo (DRUG), Bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00134459?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134459 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00134459's enrollment target sits among peer trials
434 15th of 162 higher than 148 of 162 other Bipolar Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RECRUITING · Phase 3
-
Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
COMPLETED · Phase 3
-
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
COMPLETED · Phase 3
-
Acute Treatment of Bipolar II Depression
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743245 · 434 participants · NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT06471920 · 434 participants · NA
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
- NCT07094113 · 434 participants · Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia